1. Home
  2. ATNM vs AIRE Comparison

ATNM vs AIRE Comparison

Compare ATNM & AIRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATNM
  • AIRE
  • Stock Information
  • Founded
  • ATNM 2000
  • AIRE 2021
  • Country
  • ATNM United States
  • AIRE United States
  • Employees
  • ATNM N/A
  • AIRE N/A
  • Industry
  • ATNM Biotechnology: Pharmaceutical Preparations
  • AIRE
  • Sector
  • ATNM Health Care
  • AIRE
  • Exchange
  • ATNM Nasdaq
  • AIRE Nasdaq
  • Market Cap
  • ATNM 50.2M
  • AIRE 40.7M
  • IPO Year
  • ATNM N/A
  • AIRE N/A
  • Fundamental
  • Price
  • ATNM $1.29
  • AIRE $0.52
  • Analyst Decision
  • ATNM Strong Buy
  • AIRE Hold
  • Analyst Count
  • ATNM 2
  • AIRE 1
  • Target Price
  • ATNM $4.50
  • AIRE N/A
  • AVG Volume (30 Days)
  • ATNM 306.1K
  • AIRE 39.8M
  • Earning Date
  • ATNM 11-14-2025
  • AIRE 11-12-2025
  • Dividend Yield
  • ATNM N/A
  • AIRE N/A
  • EPS Growth
  • ATNM N/A
  • AIRE N/A
  • EPS
  • ATNM N/A
  • AIRE N/A
  • Revenue
  • ATNM N/A
  • AIRE $3,043,657.00
  • Revenue This Year
  • ATNM N/A
  • AIRE $410.32
  • Revenue Next Year
  • ATNM N/A
  • AIRE $166.28
  • P/E Ratio
  • ATNM N/A
  • AIRE N/A
  • Revenue Growth
  • ATNM N/A
  • AIRE 2973.28
  • 52 Week Low
  • ATNM $1.03
  • AIRE $0.14
  • 52 Week High
  • ATNM $2.41
  • AIRE $4.49
  • Technical
  • Relative Strength Index (RSI)
  • ATNM 40.17
  • AIRE 44.13
  • Support Level
  • ATNM $1.23
  • AIRE $0.46
  • Resistance Level
  • ATNM $1.40
  • AIRE $0.55
  • Average True Range (ATR)
  • ATNM 0.09
  • AIRE 0.15
  • MACD
  • ATNM -0.01
  • AIRE -0.02
  • Stochastic Oscillator
  • ATNM 19.61
  • AIRE 6.03

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

About AIRE reAlpha Tech Corp.

ReAlpha Tech Corp is a real estate technology company. The group is engaged in an end-to-end commission-free homebuying platform. It develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for the analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability. The company's reportable segments are; Platform Services and the Rental business segment.

Share on Social Networks: